DexCom, Inc. (DXCM) All Metrics
DXCM Valuation Metrics
DXCM Stock Price Metrics
DXCM Dividend Metrics
DXCM Growth Rate Metrics
DXCM Discounted Cash Flow Metrics
| Fair Value Price | $33.27 |
| Margin of Safety | (55.50%) |
DXCM Revenue Metrics
DXCM PE Ratio Metrics
| PE Ratio | 32.03 |
| PE Ratio Avg TTM | 41.88 |
| PE Ratio Avg 3Y | 71.49 |
| Current VS TTM Avg | -23.52% |
| Current VS 3Y Avg | -55.20% |
| Current VS 5Y Avg | -71.78% |
DXCM PS Ratio Metrics
| PS Ratio | 6.12 |
| PS Ratio Avg TTM | 6.42 |
| PS Ratio Avg 3Y | 9.80 |
| Current VS TTM Avg | -4.70% |
| Current VS 3Y Avg | -37.55% |
| Current VS 5Y Avg | -54.48% |
DXCM PB Ratio Metrics
| PB Ratio | 9.98 |
| PB Ratio Avg TTM | 10.89 |
| PB Ratio Avg 3Y | 16.28 |
| Current VS TTM Avg | -8.32% |
| Current VS 3Y Avg | -38.70% |
| Current VS 5Y Avg | -47.25% |
DXCM Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 20.64 |
| PFCF Ratio Avg TTM | 35.95 |
| PFCF Ratio Avg 3Y | 63.97 |
| Current VS TTM Avg | -42.58% |
| Current VS 3Y Avg | -67.73% |
| Current VS 5Y Avg | -88.31% |
DXCM Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.51 |
| Debt/Equity Ratio Avg TTM | 0.87 |
| Debt/Equity Ratio Avg 3Y | 1.00 |
| Current VS TTM Avg | -41.38% |
| Current VS 3Y Avg | -49.00% |
| Current VS 5Y Avg | -49.59% |
DXCM PEG Ratio Metrics
| PEG Ratio | 0.66 |
| PEG Ratio Avg TTM | 0.66 |
| PEG Ratio Avg 3Y | 0.66 |
| Current VS TTM Avg | 0.00% |
| Current VS 3Y Avg | 0.00% |
| Current VS 5Y Avg | 0.00% |
DXCM FCF Yield
| FCF Yield | 4.84% |
| FCF Yield Avg TTM | 3.33% |
| FCF Yield Avg 3Y | 2.08% |
| Current VS TTM Avg | +45.21% |
| Current VS 3Y Avg | +132.44% |
| Current VS 5Y Avg | +242.91% |
DXCM Earnings Yield
| Earnings Yield | 3.12% |
| Earnings Yield Avg TTM | 2.57% |
| Earnings Yield Avg 3Y | 1.80% |
| Current VS TTM Avg | +21.37% |
| Current VS 3Y Avg | +72.96% |
| Current VS 5Y Avg | +137.13% |
DXCM EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 28.80 |
| Ev/Ebit Ratio Avg TTM | 38.63 |
| Ev/Ebit Ratio Avg 3Y | 65.25 |
| Current VS TTM Avg | -25.44% |
| Current VS 3Y Avg | -55.86% |
| Current VS 5Y Avg | -71.72% |
DXCM EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 23.03 |
| Ev/Ebitda Ratio Avg TTM | 28.03 |
| Ev/Ebitda Ratio Avg 3Y | 43.45 |
| Current VS TTM Avg | -17.85% |
| Current VS 3Y Avg | -47.00% |
| Current VS 5Y Avg | -67.08% |
DXCM EV/Assets Ratio Metrics
| Ev/Assets Ratio | 4.49 |
| Ev/Assets Ratio Avg TTM | 4.22 |
| Ev/Assets Ratio Avg 3Y | 5.88 |
| Current VS TTM Avg | +6.28% |
| Current VS 3Y Avg | -23.64% |
| Current VS 5Y Avg | -39.82% |
DXCM EV/Sales Ratio Metrics
| Ev/Sales Ratio | 6.18 |
| Ev/Sales Ratio Avg TTM | 6.63 |
| Ev/Sales Ratio Avg 3Y | 10.22 |
| Current VS TTM Avg | -6.85% |
| Current VS 3Y Avg | -39.53% |
| Current VS 5Y Avg | -55.46% |
DXCM Current Ratio Metrics
| Current Ratio | 1.88 |
| Current Ratio Avg TTM | 1.67 |
| Current Ratio Avg 3Y | 2.04 |
| Current VS TTM Avg | +12.24% |
| Current VS 3Y Avg | -8.07% |
| Current VS 5Y Avg | -40.22% |
DXCM Quick Ratio Metrics
| Quick Ratio | 1.59 |
| Quick Ratio Avg TTM | 1.44 |
| Quick Ratio Avg 3Y | 1.80 |
| Current VS TTM Avg | +10.80% |
| Current VS 3Y Avg | -11.42% |
| Current VS 5Y Avg | -43.85% |
DXCM ROIC Metrics
| ROIC | 16.61% |
| ROIC Avg 3Y | 11.07% |
| ROIC Avg 5Y | 9.62% |
| Current VS 3Y Avg | +49.98% |
| Current VS 5Y Avg | +72.69% |
| Current VS 10Y Avg | +11920.39% |
DXCM Return on Assets Metrics
| ROA | 13.19 |
| ROA Avg TTM | 11.04 |
| ROA Avg 3Y | 9.26 |
| Current VS TTM Avg | +19.47% |
| Current VS 3Y Avg | +42.40% |
| Current VS 5Y Avg | +49.46% |
DXCM Return on Equity Metrics
| ROE | 30.46 |
| ROE Avg TTM | 28.93 |
| ROE Avg 3Y | 25.01 |
| Current VS TTM Avg | +5.29% |
| Current VS 3Y Avg | +21.78% |
| Current VS 5Y Avg | +32.73% |
DXCM Net Profit Margin Metrics
| Net Profit Margin | 17.94% |
| Net Profit Margin Avg TTM | 16.12% |
| Net Profit Margin Avg 3Y | 14.73% |
| Current VS TTM Avg | +11.32% |
| Current VS 3Y Avg | +21.81% |
| Current VS 5Y Avg | +15.26% |
Last Updated: Thursday, June 11, 2026
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach